Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea flag South Korea · Delayed Price · Currency is KRW
21,350
+1,730 (8.82%)
Aug 12, 2026, 3:30 PM KST

Kolon TissueGene Revenue

Kolon TissueGene had revenue of 1.41B KRW in the quarter ending March 31, 2026, with 9.49% growth. This brings the company's revenue in the last twelve months to 5.28B, up 2.95% year-over-year. In the year 2025, Kolon TissueGene had annual revenue of 5.16B with 1.68% growth.

Revenue (ttm)
5.28B
Revenue Growth
+2.95%
P/S Ratio
315.68
Revenue / Employee
182.10M
Employees
29
Market Cap
1.67T

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20255.16B85.27M1.68%
Dec 31, 20245.07B1.37B36.90%
Dec 31, 20233.71B-5.75B-60.81%
Dec 31, 20229.46B5.45B136.22%
Dec 31, 20214.00B447.31M12.58%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Chabiotech1.29T
SK bioscience665.42B
Hugel479.57B
Onconic Therapeutics67.20B
Pharmicell23.94B
OliX Pharmaceuticals17.26B
Voronoi7.51B
AbClon4.74B
Revenue Rankings

Kolon TissueGene News

More News